Jimmy Limdi, MBBS, FRCP, FACG
Dr
The Pennine Acute NHS Trust ; Institute of inflammation & Repair, University of Manchester
Manchester, GB
Jimmy K. Limdi, FRCP, FACG1, Alison Rose2, Declan Noone, MSC, MEng2, Luisa Avedano3, Bu Hayee, BSc, MBBS, PhD, FRCP4, Andreas Sturm, MD5, Laurent Peyrin-Biroulet, MD, PhD6, Alan Finnegan, PhD, RN, FRCN, FAAN7, Seb Tucknott8, Johan Burisch, MD, PhD9, Alan J. Lobo, MBBS, MD, MRCP10, Helen Terry11, Gionata Fiorino, MD, PhD12, Jonathan Evans, BSc2
1Northern Care Alliance, Bury, England, United Kingdom; 2HCD Economics, Daresbury, England, United Kingdom; 3EFCCA, Brussels, Brussels Hoofdstedelijk Gewest, Belgium; 4King's College Hospital, London, England, United Kingdom; 5DRK Kliniken, Berlin, Berlin, Germany; 6Lorraine University, Vandoeuvre-lès-Nancy, Lorraine, France; 7University of Chester, Chester, England, United Kingdom; 8IBDrelief, Brighton, England, United Kingdom; 9North Zealand Hospital, Hillerød, Hovedstaden, Denmark; 10Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, England, United Kingdom; 11Crohn's & Colitis UK, Hatfield, England, United Kingdom; 12Istituto Clinico Humanitas, Milan, Lombardia, Italy
Introduction: The living with Ulcerative Colitis (UC), identifying the socioeconomic burden in Europe (LUCID) study was a descriptive, retrospective, cross-sectional, European, multi-site, bottom-up Burden of Illness research study carried out by HCD Economics and the University of Chester in partnership with Crohn’s and Colitis UK.
Methods: The primary objective of the LUCID study was to quantify the existing UC-related costs for each country and by disease severity. The study population was recruited through gastroenterologists (surveyed between Aug 2018-Feb 2019) and included adult patients diagnosed with UC by endoscopy and histology, at least 24 months prior the index date (date of clinical consultation). The study cohort population consisted of two arms; Arm 1: Patients with moderate or severe UC status at initiation of documentation period (12 months prior the index date) and, Arm 2: Patients with moderate or severe UC that achieved mild UC or remission at initiation of documentation period. Physician completed questionnaires (CRF) captured clinical information, direct medical costs and some direct non-medical costs. Patients completed a corresponding public patient involvement and engagement (PPIE) form which captured further direct non-medical costs and indirect costs. The economic burden per-patient was calculated by multiplying the quantities of the resource use collected with the national unit price. Total costs could only be calculated for patients with completed PPIE forms.
Results: Completed physician-reported forms (CRF) and PPIE forms were assessed for 1,658 patients. Of these, 1001 (60.7%) and 648 (29.3%) patients were in arm 1 and arm 2 respectively, with 9 patients unable to be assigned to either arm. Total average EU cost per patient in the last 12 months was €8,833.94 in arm 1 and €6,512.74 in patients in arm 2 with direct medical costs per patient amounting to €4381.70 in arm 1 and €3078.48 in arm 2. Direct non-medical costs per patient were €1353.93 for arm 1 and €1128.37 for arm 2. Societal costs per patient amounted to €3098.31 of the total cost for arm 1 and €2305.89 for arm 2.
Discussion: These preliminary results suggest that non-medical costs and indirect costs make up substantial proportions of the overall cost implying that the cost of treatment constitutes only a part of the overall burden of UC. Further analysis is planned to identify the drivers of costs in each arm in order to make comparisons between them.
Citation: Jimmy K. Limdi, FRCP, FACG; Alison Rose; Declan Noone, MSC, MEng; Luisa Avedano; Bu Hayee, BSc, MBBS, PhD, FRCP; Andreas Sturm, MD; Laurent Peyrin-Biroulet, MD, PhD; Alan Finnegan, PhD, RN, FRCN, FAAN; Seb Tucknott; Johan Burisch, MD, PhD; Alan J. Lobo, MBBS, MD, MRCP; Helen Terry; Gionata Fiorino, MD, PhD; Jonathan Evans, BSc. P1388 - THE SOCIOECONOMIC IMPACT OF LIVING WITH ULCERATIVE COLITIS: A BURDEN OF ILLNESS STUDY. Program No. P1388. ACG 2019 Annual Scientific Meeting Abstracts. San Antonio, Texas: American College of Gastroenterology.